View Older Stories View More Recent Stories
-
Illumina launches TruPath Genome sequencing technology
-
Illumina announces NovaSeq X system upgrades over 18 months
-
Stifel Reiterates Buy Rating on Illumina (ILMN)
-
Canaccord Genuity Reiterates Hold Rating on Illumina (ILMN)
-
Canaccord Genuity Reiterates Hold Rating on Illumina (ILMN)
-
Illumina (ILMN) Tops Q4 EPS by 13c, provides guidance
-
Illumina (ILMN) PT Raised to $150 at Canaccord Genuity
-
Illumina receives CMS reimbursement for cancer genomic test
-
Illumina (ILMN) PT Raised to $155 at Stifel
-
Illumina launches billion cell dataset for drug discovery AI
-
Illumina reports preliminary Q4 revenue of $1.16 billion, up 5%
-
Illumina launches cloud-based multiomic research software platform
-
Illumina (ILMN) Sees Multiple Growth Levers Over 3-5 Years - Stifel
-
Illumina study finds whole-genome sequencing captures 90% of genetic signals
-
Illumina reports 40 customers using protein prep solution across 16 sites
-
China lifts export ban on Illumina effective November 10
-
Illumina (ILMN) PT Raised to $112 at Canaccord Genuity
-
Illumina (ILMN) Tops Q3 EPS by 17c; offers guidance
-
Guggenheim Reiterates Buy Rating on Illumina (ILMN)
-
Illumina constellation technology identifies hard-to-detect genetic variants
-
Illumina launches 5-base solution for genomic and epigenomic analysis
-
Illumina (ILMN) 2100 contracts of October 90 puts trade, share price down 4.2%
-
Illumina launches BioInsight business for data and AI solutions
-
BofA introduces Top 10 U.S. ideas for Q4 2025
-
Illumina partners with pharma companies on KRAS cancer diagnostics
-
Alnylam joins Alliance for Genomic Discovery genomic dataset
-
Illumina launches protein prep assay for drug discovery research
-
Illumina (ILMN) PT Raised at RBC Capital; 'Time For Investors To Re-Visit ILMN'
-
Stocks expected to have increasing option volume: ILMN BOOT FIVN ROKU KLAC NET SVV BE TREE BOOT KLAC PARA CSX PLTR
-
Illumina (ILMN) Tops Q2 EPS by 18c; offers guidance
-
Illumina launches enhanced cancer research assay with faster results
-
Scotiabank Downgrades Illumina (ILMN) to Sector Perform
-
Citi Downgrades Illumina (ILMN) to Sell
-
Evercore Lists Additions to TAP Outperform List of Life Science & Diagnostic Tools Names
-
Bernstein on US Life Science Tools & Diagnostics: 'Why We're More Bullish...'
-
iRhythm Technologies (IRTC) announces Board changes
-
Bernstein Reiterates Market Perform Rating on Illumina (ILMN) Post SomaLogic Acquisition
-
Illumina (ILMN) to acquire SomaLogic
-
Standard BioTools (LAB) Sells SomaLogic to Illumina (ILMN)
-
Illumina (ILMN) PT Raised to $99 at Canaccord Genuity Following CEO Podcast
-
Piper Sandler on Illumina (ILMN): 'Near-Term Headwinds, but We're Optimistic About 26/27'
-
Illumina (ILMN) unveils PromoterAI
-
Illumina (ILMN) expands clinical oncology portfolio unlocking new standard of care and access to precision therapies
-
Stifel Reiterates Buy Rating on Illumina (ILMN)
-
Citi names 3 stocks as its new top picks in the Life Science sector
-
Illumina (ILMN) Launches DRAGEN v4.4 powers clinical oncology research and multiomic applications
-
Increasing unusual call option volume: PHAT CNH AXL RUN PPG SHLS AS AZUL ILMN
-
Illumina (ILMN) PT Lowered to $87 at Canaccord Genuity
-
These 2 sectors are under-owned, Barclays says and advises where to invest
-
Illumina (ILMN) PT Raised to $89 at TD Cowen Despite a 'Difficult Macro'
